Clinical manifestations and inflammatory profiles in serum and skin of patients with neutrophilic dermatoses associated with adult onset immune deficiency due to autoantibodies to Interferon-gamma (IFN-Î³)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20171103001

Enrollment

Registered

2017-11-03

Start date

2017-11-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical manifestations and inflammatory profiles in serum and skin of patients with neutrophilic dermatoses associated with adult onset immune deficiency due to autoantibodies to Interferon&#45

Interventions

patients with neutrophilic dermatoses associated with adult onset immune deficiency due to autoantibodies to Interferon&#45

gamma (IFN&#45

Î³)

Health Services Research

patients with neutrophilic dermatoses

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. age 18-60 years old 2. evidence of Anti-IFN Æ³ autoantibodies by one of these techniques luciferace immunoprecipitation system (LIPS), anti-IFN Æ³ autoantibody ELISA, particle-based technique, immunobloting technique, modified competitive inhibition assay using Bioplex cytokine assay 3. negative for anti-HIV antibody 4. equal or more than 2 times infects below agents and confirmed by culture, PCR or biopsy - nontuberculous mycobacterium (NTM) - disseminated fungal infections (e.g., penicilliosis marneffei, cryptococcosis, histoplasmosis) - disseminated herpes zoster infection non-typhoidal Salmonella bacteremia

Exclusion criteria

Exclusion criteria: 1.history of cancer 2.using corticosteroids or other immunosuppressive agents within 4 weeks before screening or day that found opportunistic infection

Design outcomes

Primary

Measure	Time frame
Clinical manifestation, opportunistic infection and response to treatment 0 months, 3 months, 6 months, 12 months physical examination,Compare cytokines, chemokines and adhesion molecule between during neutrophilic dermatosis and non 0 months, 3 months, 6 months, 12 months ProcartaPlexÂ® Multiplex Immunoassay Panels ,Relationship of cytokines in serum and skin of neutrophilic dermatoses 0 months, 3 months, 6 months, 12 months polymerase chain reaction (PCR) and immunohistochemistry	—

Measure

Time frame

Clinical manifestation, opportunistic infection and response to treatment 0 months, 3 months, 6 months, 12 months physical examination,Compare cytokines, chemokines and adhesion molecule between during neutrophilic dermatosis and non 0 months, 3 months, 6 months, 12 months ProcartaPlexÂ® Multiplex Immunoassay Panels ,Relationship of cytokines in serum and skin of neutrophilic dermatoses 0 months, 3 months, 6 months, 12 months polymerase chain reaction (PCR) and immunohistochemistry

—

Secondary

Measure	Time frame
Relationship of autoantibody levels and autoantibody subclasses to IFN-Î³ with skin manifestation 0 months, 3 months, 6 months, 12 months anti-IFNÎ³ autoantibodies ELISA	—

Countries

Thailand

Contacts

Public ContactPawinee Rerknimitr

Faculty of Medicine, Chulalongkorn University

pawinee.r@chula.ac.th02-2564253

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Clinical manifestations and inflammatory profiles in serum and skin of patients with neutrophilic dermatoses associated with adult onset immune deficiency due to autoantibodies to Interferon&#45;gamma (IFN&#45;Î³)

Conditions

Related papers

Interventions

Sponsors

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Contacts

Outcome results

Clinical manifestations and inflammatory profiles in serum and skin of patients with neutrophilic dermatoses associated with adult onset immune deficiency due to autoantibodies to Interferon-gamma (IFN-Î³)